MacQueen Kathleen M, Dlamini Sarah, Perry Brian, Okumu Eunice, Sortijas Steve, Singh Chitra, Pillay Diantha, Majors Alesha, Jerome Sonja, Watson Sharon, Karim Salim Abdool, Karim Quarraisha Abdool, Mansoor Leila E
Global Health Research, FHI 360, 359 Blackwell Street, Suite 200, Durham, NC, 27701, USA.
CAPRISA, University of KwaZulu-Natal, Durban, South Africa.
AIDS Behav. 2016 Nov;20(11):2682-2691. doi: 10.1007/s10461-016-1339-4.
CAPRISA 008, an open-label extension study of tenofovir gel with coitally-related dosing, provided an opportunity to explore the relationship between product adherence and gender dynamics in a context where women knew they were receiving an active product with evidence of HIV prevention effectiveness. Interviews with 63 CAPRISA 008 participants and 13 male partners in KwaZulu-Natal, South Africa, highlighted that the process of negotiating gel use was determined in part by relationship dynamics including the duration of the relationship, the living situation, an evaluation of the relationship (e.g., partner intimacy and relationship expectations) and culturally-defined steps for formalizing the relationship. While disclosure facilitated adherence for many, others reported using the gel effectively with no disclosure, and in some situations disclosure was a barrier to adherence. Women should be supported in their choice about what to disclose and have opportunity to use this and similar products without their partners' knowledge or acquiescence.
CAPRISA 008是一项关于替诺福韦凝胶性交相关给药的开放标签扩展研究,该研究提供了一个机会,在女性知道自己正在接受一种有预防艾滋病毒有效性证据的活性产品的背景下,探索产品依从性与性别动态之间的关系。对南非夸祖鲁-纳塔尔省63名CAPRISA 008参与者和13名男性伴侣进行的访谈强调,协商使用凝胶的过程部分取决于关系动态,包括关系的持续时间、生活状况、对关系的评估(如伴侣亲密程度和关系期望)以及关系正式化的文化定义步骤。虽然披露信息有助于许多人坚持使用,但其他人报告说在未披露信息的情况下也能有效使用凝胶,而且在某些情况下,披露信息是坚持使用的障碍。应支持女性选择披露内容的权利,并有机会在伴侣不知情或未默许的情况下使用该产品及类似产品。